Loading patent…
AssigneeNovartis AG
InventorsAndreas Clemens, Martina Junge, Jeffrey David Kearns, Ufuk Olgac, Jessica Voegeler
Estimating the term…
The invention relates to methods for treating ocular disease with a VEGF antagonist. In particular, the invention relates to methods for treating ocular disease, e.g., neovascular age-related macular degeneration (nAMD), in a patient, the method comprising administering to the patient one initial dose of a VEGF antagonist, e.g., brolucizumab, followed by a maintenance regimen of additional doses of the VEGF antagonist administered in an administration interval of at least 8 weeks. In particular, the invention relates to methods for treating ocular disease, in particular neovascular age-related macular degeneration (nAMD), in a patient pretreated with one or more doses of a VEGF antagonist B, the method comprising administering to the patient an initial dose of a VEGF antagonist A followed by one or more additional doses of a VEGF antagonist A in an administration interval according to a maintenance regimen of the VEGF antagonist A for the treatment of the ocular disease.
1-2. (canceled)
A method for treating ocular disease in a patient, the method comprising administering to the patient an initial dose of a VEGF antagonist followed by one or more additional doses of the VEGF antagonist, wherein the one or more additional doses of the VEGF antagonist are administered at least 8 weeks after the initial dose and each of the one or more additional doses after the initial dose are administered in an administration interval of at least 8 weeks.
(canceled)
A method for treating ocular disease in a patient, the method comprising administering to the patient one initial dose of a VEGF antagonist followed by a maintenance regimen of additional doses of the VEGF antagonist administered in an administration interval of at least 8 weeks.
(canceled)
17-18. (canceled)
(canceled)
(canceled)
28-66. (canceled)
A method for treating ocular disease in a patient pretreated with one or more doses of a VEGF antagonist B, the method comprising administering to the patient an initial dose of a VEGF antagonist A followed by one or more additional doses of the VEGF antagonist A in an administration interval of no less than about 8 weeks, and/or as individualized by a physician based on a disease activity assessment.
A method for treating ocular disease in a patient pretreated with one or more doses of a VEGF antagonist B, the method comprising administering to the patient an initial dose of a VEGF antagonist A followed by one or more additional doses of the VEGF antagonist A in an administration interval according to a maintenance regimen of the VEGF antagonist A for the treatment of the ocular disease.
(canceled)
86-91. (canceled)
(canceled)
(canceled)
100-146. (canceled)
Dependencies are inferred from the claim text.